Aurobindo Pharma Ltd has completed the acquisition of certain commercial operations in Western Europe from Actavis plc.
In January this year, the Hyderabad-based Aurobindo Pharma had entered in to an agreement with Actavis to acquire its personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in seven European countries for €30 million. Both the companies had also inked a long term commercial and supply arrangement.
``The acquisition will make Aurobindo one of the leading Indian pharmaceutical companies in Europe with a top 10 position in several key markets,’’ Muralidharan, Senior Vice-President of European operations for Aurobindo said in a statement on Tuesday.
Aurobindo would work to combine the strength of both enterprises in these markets and to identify and maximise all opportunities. ``We will continue to collaborate with Actavis to ensure business continuity and a smooth transition. In parallel, we will work closely with the acquired management teams to achieve a rapid and successful integration,’’ he added.
Aurobindo’s scrip gained 4.67 per cent on the Bombay Stock Exchange on Tuesday to end at Rs 534.70.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.